Filtern
Erscheinungsjahr
Dokumenttyp
Volltext vorhanden
- ja (1097)
Gehört zur Bibliographie
- nein (1097)
Schlagworte
- Heavy Ion Experiments (20)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (9)
- LHC (9)
- SARS-CoV-2 (8)
- Heavy-ion collision (6)
- COVID19-NMR (5)
- ALICE experiment (4)
- Quark-Gluon Plasma (4)
- Solution NMR spectroscopy (4)
- 5′-UTR (3)
- ALICE (3)
- Collective Flow (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- RNA (3)
- pp collisions (3)
- ACLF (2)
- BCR/ABL (2)
- Beauty production (2)
- Charm physics (2)
- Epilepsy (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy Quark Production (2)
- Jets (2)
- Lepton-Nucleon Scattering (experiments) (2)
- NMR spectroscopy (2)
- Non-structural protein (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Philadelphia chromosome (2)
- QCD (2)
- Seizure (2)
- Single electrons (2)
- Solution NMR-spectroscopy (2)
- acute-on-chronic liver failure (2)
- glioblastoma (2)
- proteomics (2)
- radiotherapy (2)
- 19F (1)
- 2-deoxyglucose (2-DG) (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 900 GeV (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- Abl kinase inhibitors (1)
- Active middle ear implants (1)
- Allosteric inhibition (1)
- Alternating Phase Focusing (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- B cell receptor (1)
- B. subtilis (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Beam dynamics simulation (1)
- Beskid Niski Mts (1)
- Biogeochemistry (1)
- Biomarker (1)
- Bone conduction devices (1)
- Boosted Jets (1)
- Brain tumor (1)
- Business strategy in drug development (1)
- CAKUT (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COVID-19 (1)
- CPTAC (1)
- CRC65 (1)
- Carbon cycle (1)
- Cementation (1)
- Centrality Class (1)
- Centrality Selection (1)
- Ceramic (1)
- Chemical communication (1)
- Chocó rainforest (1)
- Chronic disease (1)
- Communication center (1)
- Comparative genomics (1)
- Comparison with QCD (1)
- Consensus statement (1)
- Continuous wave (1)
- Core marking (1)
- Costs (1)
- Covid19-NMR (1)
- Covid19-nmr (1)
- DNA-PAINT (1)
- Data sharing (1)
- Depression (1)
- Diagnostic imaging (1)
- Drug screens (1)
- Drug therapy (1)
- E. coli (1)
- Ecosystem ecology (1)
- Ecuador (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Everolimus (1)
- Evolution (1)
- FBS (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Forest ecology (1)
- Functionally-impaired elderly (1)
- Fungi (1)
- Gene expression profiling (1)
- General practice (1)
- Genetics (1)
- Glioma (1)
- HBT (1)
- HOD (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Health policy (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- High-dose chemotherapy (1)
- High-throughput screening (1)
- Holmes tremor (1)
- Hyperons (1)
- Immunology (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Invertebrates (1)
- Ionisation energy loss (1)
- Ixodes ricinus (1)
- Jet Physics (1)
- Jet Substructure (1)
- Lenalidomide (1)
- Leukemias (1)
- Linear accelerator (1)
- Localized defecation (1)
- MTOR inhibitor (1)
- Macrodomain (1)
- Magnetic resonance imaging (1)
- Material budget (1)
- Meriç River (1)
- Microplastic (1)
- Mid-rapidity (1)
- Minimal invasive (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mixture toxicity (1)
- Molecular biology (1)
- Molecular matched therapy (1)
- Molecular medicine (1)
- Molecular modelling (1)
- Molecular profiling (1)
- Molecular therapy (1)
- Mollusks (1)
- Monolithic crown (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple myeloma (1)
- Multiple stressors (1)
- NAFL (1)
- NASH (1)
- Neural network (1)
- Neuroscience (1)
- Non-small cell lung cancer (1)
- Nonlinear beam dynamics (1)
- Nuclear modification factor (1)
- Nucleus (1)
- Oncology (1)
- Osimertinib (1)
- PYTHIA (1)
- Pain (1)
- Particle and Resonance Production (1)
- Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (1)
- Pb–Pb (1)
- Physiology (1)
- Plant symbiosis (1)
- Pond snail (1)
- Positron emission tomography (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Protein drugability (1)
- Proteins (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- Quality of life (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- RNA genome (1)
- RNASolution-state NMR (1)
- RSL curve (1)
- Rapidity Range (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Rhabdomyoma (1)
- SL1 (1)
- SL5a (1)
- SL5b (1)
- SL5b + c (1)
- SL5c (1)
- SLC20A1 (1)
- SPSS (1)
- Second-line treatment (1)
- Self-assessment (1)
- Single muons (1)
- Sociodemographic characteristics (1)
- Strangeness (1)
- Subependymal giant cell astrocytoma (1)
- Surgery (1)
- Systematic Uncertainty (1)
- TP53 mutation status (1)
- TR (1)
- TSC (1)
- Target validation (1)
- Targeted therapy (1)
- Technical data (1)
- Tet-inducible system (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Urban ecology (1)
- Vasculitis (1)
- Vector Boson Production (1)
- Warburg effect (1)
- Xenon-based gas mixture (1)
- Zirconia (1)
- aboveground biomass (1)
- accessory proteins (1)
- acute coronary syndrome (1)
- acute decompensation (1)
- acute lymphatic leukemia (1)
- adult (1)
- aegean (1)
- aging (1)
- allosteric inhibition (1)
- amplicon sequencing (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- archeological sea-level limiting points (1)
- arthritis (1)
- artifacts (1)
- artificial feeding (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- biochemistry (1)
- biodiversity (1)
- biophysics (1)
- bipartite networks (1)
- bladder exstrophy-epispadias complex (1)
- cancer (1)
- cannabidiol (1)
- cannabinoids (1)
- cannabis (1)
- cell-free protein synthesis (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- chronosequence (1)
- cirrhosis (1)
- clinical trial (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- computed tomography (1)
- copeptin (1)
- dE/dx (1)
- data quality (1)
- deadwood (1)
- decomposition (1)
- detector (1)
- diffusion-weighted magnetic resonance imaging (1)
- doxycycline (1)
- drug response (1)
- dysbiosis (1)
- ectosomes (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- females (1)
- fluorine (1)
- folding (1)
- foraminifera (1)
- foraminifers (1)
- fragment screening (1)
- fragment-based screening (1)
- functional genetics (1)
- geophysical prospections (1)
- global change (1)
- glycolysis (1)
- guidelines (1)
- habitat destruction (1)
- head-and-neck cancer (1)
- healthy subjects (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- hypoxia-induced cell death (1)
- immunotherapy (1)
- inducible gene expression (1)
- inflammation (1)
- interferon gamma (1)
- interstitial lung disease (1)
- intrinsically disordered region (1)
- isocaloric ketogenic diet (1)
- kidney formation (1)
- kinetics (1)
- land use (1)
- lichen diversity (1)
- lichenized fungi (1)
- liver (1)
- lung cancer (1)
- mTOR inhibitor (1)
- magnetic gradiometry (1)
- magnetic resonance imaging (1)
- mechanical ventilation (1)
- medulloblastoma (1)
- medulloblastoma resection (1)
- meta-stable structures (1)
- metabolic cancer therapy (1)
- metabolic syndromes (1)
- metastasis (1)
- microbes (1)
- microbiome (1)
- micropalaeontology (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- mitochondria (1)
- model psychosis (1)
- modularity (1)
- molecular therapy (1)
- mortality (1)
- multicenter study (1)
- multiplexed immunofluorescence (1)
- myocardial infarction (1)
- myositis (1)
- myxomycete (1)
- neoadjuvant chemoradiotherapy (1)
- neoepitopes (1)
- neurodegeneration (1)
- new records (1)
- newly diagnosed glioblastoma (1)
- nivolumab (1)
- nonstructural proteins (1)
- nymphs (1)
- oral cavity cancer (1)
- palatal tremor (1)
- patient stratification (1)
- portal hypertension (1)
- portosystemic shunt (1)
- posterior fossa masses (1)
- predictive biomarker (1)
- proteins (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- randomized (1)
- rare species (1)
- rct (1)
- reassembly (1)
- registry (1)
- reproducibility (1)
- resilience (1)
- resistance (1)
- respiratory failure (1)
- riboswitches (1)
- rigor (1)
- saprotrophic fungi (1)
- sea-level indicator (1)
- sequential ALK-inhibitor therapy (1)
- specialization (1)
- spectra (1)
- spontaneous portosystemic shunt (1)
- standardization (1)
- structural biology (1)
- structural proteins (1)
- subgrouping (1)
- targeted therapy (1)
- temozolomide (1)
- tetracycline (1)
- tetrahydrocannabinol (1)
- transcription (1)
- transovarial transmission (1)
- transstadial transmission (1)
- trees (1)
- troponin (1)
- tumor metabolism (1)
- tumor-infiltrating lymphocytes (1)
- unmethylated MGMT (1)
- urinary tract development (1)
- vector (1)
- zebrafish development (1)
- “gatekeeper” mutation T315I (1)
- √sN N = 2.76 TeV (1)
Institut
- Physik (1014)
- Frankfurt Institute for Advanced Studies (FIAS) (937)
- Informatik (904)
- Medizin (49)
- Biowissenschaften (12)
- Biochemie, Chemie und Pharmazie (10)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (9)
- Geowissenschaften (4)
- Biodiversität und Klima Forschungszentrum (BiK-F) (3)
- Georg-Speyer-Haus (3)
Exported proteases of Helicobacter pylori (H. pylori) are potentially involved in pathogen-associated disorders leading to gastric inflammation and neoplasia. By comprehensive sequence screening of the H. pylori proteome for predicted secreted proteases, we retrieved several candidate genes. We detected caseinolytic activities of several such proteases, which are released independently from the H. pylori type IV secretion system encoded by the cag pathogenicity island (cagPAI). Among these, we found the predicted serine protease HtrA (Hp1019), which was previously identified in the bacterial secretome of H. pylori. Importantly, we further found that the H. pylori genes hp1018 and hp1019 represent a single gene likely coding for an exported protein. Here, we directly verified proteolytic activity of HtrA in vitro and identified the HtrA protease in zymograms by mass spectrometry. Overexpressed and purified HtrA exhibited pronounced proteolytic activity, which is inactivated after mutation of Ser205 to alanine in the predicted active center of HtrA. These data demonstrate that H. pylori secretes HtrA as an active protease, which might represent a novel candidate target for therapeutic intervention strategies.
Background: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials. The aim of this study was to assess the efficacy of thymostimulin in a phase III trial. Methods: The study was designed as a prospective randomised, placebo-controlled, double-blind, multicenter clinical phase III trial. Between 10/2002 and 03/2005, 135 patients with locally advanced or metastasised HCC (Karnofsky [greater than or equal to]60% / Child-Pugh [less than or equal to]12) were randomised to receive thymostimulin 75 mg s.c. 5x/week or placebo stratified according to liver function. Primary endpoint was twelve-month survival, secondary endpoints overall survival (OS), time to progression (TTP), tumor response, safety and quality of life. A subgroup analysis according to liver function, KPS and tumor stage (Okuda, CLIP and BCLC) formed part of the protocol. Current Controlled Trials ISRCTN64487365. Results: Twelve-month survival was 28% [95%CI 17-41; treatment] and 32% [95%CI 19-44; control] with no significant differences in median OS (5.0 [95% CI 3.7-6.3] vs. 5.2 [95% CI 3.5-6.9] months; p=0.87, HR=1.04 [95% CI 0.7-1.6]) or TTP (5.3 [95%CI 2.0-8.6] vs. 2.9 [95%CI 2.6-3.1] months; p=0.60, HR=1.13 [95% CI 0.7-1.8]). Adjustment for liver function, Karnofsky status or tumor stage did not affect results. While quality of life was similar in both groups, fewer patients on thymostimulin suffered from accumulating ascites and renal failure. Conclusions: In our phase III trial, we found no evidence of any benefit to thymostimulin in the treatment of advanced HCC and there is therefore no justification for its use as single-agent treatment. The effect of thymostimulin on hepato-renal function requires further confirmation. trial registration: Current Controlled Trials ISRCTN64487365
Gene-modified autologous hematopoietic stem cells (HSC) can provide ample clinical benefits to subjects suffering from X-linked chronic granulomatous disease (X-CGD), a rare inherited immunodeficiency characterized by recurrent, often life-threatening bacterial and fungal infections. Here we report on the molecular and cellular events observed in two young adults with X-CGD treated by gene therapy in 2004. After the initial resolution of bacterial and fungal infections, both subjects showed silencing of transgene expression due to methylation of the viral promoter, and myelodysplasia with monosomy 7 as a result of insertional activation of ecotropic viral integration site 1 (EVI1). One subject died from overwhelming sepsis 27 months after gene therapy, whereas a second subject underwent an allogeneic HSC transplantation. Our data show that forced overexpression of EVI1 in human cells disrupts normal centrosome duplication, linking EVI1 activation to the development of genomic instability, monosomy 7 and clonal progression toward myelodysplasia.
The first measurement of two-pion Bose–Einstein correlations in central Pb–Pb collisions at √sNN=2.76 TeV at the Large Hadron Collider is presented. We observe a growing trend with energy now not only for the longitudinal and the outward but also for the sideward pion source radius. The pion homogeneity volume and the decoupling time are significantly larger than those measured at RHIC.
Inclusive transverse momentum spectra of primary charged particles in Pb–Pb collisions at √sNN=2.76 TeV have been measured by the ALICE Collaboration at the LHC. The data are presented for central and peripheral collisions, corresponding to 0–5% and 70–80% of the hadronic Pb–Pb cross section. The measured charged particle spectra in |η|<0.8 and 0.3<pT<20 GeV/c are compared to the expectation in pp collisions at the same sNN, scaled by the number of underlying nucleon–nucleon collisions. The comparison is expressed in terms of the nuclear modification factor RAA. The result indicates only weak medium effects (RAA≈0.7) in peripheral collisions. In central collisions, RAA reaches a minimum of about 0.14 at pT=6–7 GeV/c and increases significantly at larger pT. The measured suppression of high-pT particles is stronger than that observed at lower collision energies, indicating that a very dense medium is formed in central Pb–Pb collisions at the LHC.
The inclusive charged particle transverse momentum distribution is measured in proton–proton collisions at s=900 GeV at the LHC using the ALICE detector. The measurement is performed in the central pseudorapidity region (|η|<0.8) over the transverse momentum range 0.15<pT<10 GeV/c. The correlation between transverse momentum and particle multiplicity is also studied. Results are presented for inelastic (INEL) and non-single-diffractive (NSD) events. The average transverse momentum for |η|<0.8 is 〈pT〉INEL=0.483±0.001 (stat.)±0.007 (syst.) GeV/c and 〈pT〉NSD=0.489±0.001 (stat.)±0.007 (syst.) GeV/c, respectively. The data exhibit a slightly larger 〈pT〉 than measurements in wider pseudorapidity intervals. The results are compared to simulations with the Monte Carlo event generators PYTHIA and PHOJET.
Rapidity and transverse momentum dependence of inclusive J/ψ production in pp collisions at √s=7 TeV
(2011)
The ALICE experiment at the LHC has studied inclusive J/ψ production at central and forward rapidities in pp collisions at √s=7 TeV. In this Letter, we report on the first results obtained detecting the J/ψ through the dilepton decay into e+e− and μ+μ− pairs in the rapidity ranges |y|<0.9 and 2.5<y<4, respectively, and with acceptance down to zero pT. In the dielectron channel the analysis was carried out on a data sample corresponding to an integrated luminosity Lint=5.6 nb−1 and the number of signal events is NJ/ψ=352±32(stat.)±28(syst.); the corresponding figures in the dimuon channel are Lint=15.6 nb−1 and NJ/ψ=1924±77(stat.)±144(syst.). The measured production cross sections are σJ/ψ(|y|<0.9)=10.7±1.0(stat.)±1.6(syst.)−2.3+1.6(syst.pol.)μb and σJ/ψ(2.5<y<4)=6.31±0.25(stat.)±0.76(syst.)−1.96+0.95(syst.pol.)μb. The differential cross sections, in transverse momentum and rapidity, of the J/ψ were also measured.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Explosive volcanism affects weather and climate. Primary volcanic ash particles which act as ice nuclei (IN) can modify the phase and properties of cold tropospheric clouds. During the Eyjafjallajökull volcanic eruption we have measured the highest ice nucleus number concentrations (>600 L) in our record of 2 years of daily IN measurements in central Germany. Even in Israel, located about 5000 km away from Iceland, IN were as high as otherwise only during desert dust storms. These measurements are the only ones available on the properties of IN in the Eyjafjallajökull plume. The measured high concentrations and high activation temperature (−8 °C) point to an important impact of volcanic ash on microphysical and radiative properties of clouds through enhanced glaciation.